Literature DB >> 29910589

Residual SYNTAX score II and complex percutaneous coronary interventions.

Levent Cerit1.   

Abstract

Entities:  

Year:  2017        PMID: 29910589      PMCID: PMC6000897          DOI: 10.1016/j.jsha.2017.11.004

Source DB:  PubMed          Journal:  J Saudi Heart Assoc        ISSN: 1016-7315


× No keyword cloud information.
To the Editor, Salvatore et al. [1] reported that SYNTAX score II (SS-II) might represent a useful tool to predict clinical events not only in ideal stable patients, but also in an unrestricted, real world population of patients with acute coronary syndrome and severe coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). SS-II briefly contains six clinical variables (age, sex, creatinine clearance, peripheral vascular disease, chronic obstructive pulmonary disease, and left ventricular ejection fraction) and two anatomical variables (anatomical SS and unprotected left main CAD) [2]. Residual SS (rSS) was designed and validated to quantify the burden of residual CAD after PCI. SS-II indicated a superior predictability for long-term mortality compared with SS [3]. SS-II may be a more useful tool than SS for predicting no-reflow phenomenon after primary PCI [4]. Additionally, prognostic significance of SS-II is widening, and it is applicable for clinical utility in valvular heart disease [5]. Residual SS-II, including rSS, postprocedural left ventricular ejection fraction, and postprocedural creatinine clearance might be a usefull tool to predict major adverse cardiac events and all-cause mortality. In this context, correlation of this study’s result with residual SS-II might be beneficial.
  5 in total

1.  Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.

Authors:  Vasim Farooq; David van Klaveren; Ewout W Steyerberg; Emanuele Meliga; Yvonne Vergouwe; Alaide Chieffo; Arie Pieter Kappetein; Antonio Colombo; David R Holmes; Michael Mack; Ted Feldman; Marie-Claude Morice; Elisabeth Ståhle; Yoshinobu Onuma; Marie-angèle Morel; Hector M Garcia-Garcia; Gerrit Anne van Es; Keith D Dawkins; Friedrich W Mohr; Patrick W Serruys
Journal:  Lancet       Date:  2013-02-23       Impact factor: 79.321

2.  Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction.

Authors:  Mahmut Yesin; Metin Çağdaş; Macit Kalçık; Mahmut Uluganyan; Süleyman Çağan Efe; İbrahim Rencüzoğulları; Yavuz Karabağ; Mustafa Ozan Gürsoy; Süleyman Karakoyun
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-29       Impact factor: 2.357

3.  SYNTAX Score-II Predicts Long-Term Mortality in Patients Who Underwent Left Main Percutaneous Coronary Intervention Treated With Second-Generation Drug-Eluting Stents.

Authors:  Jiqiang He; Hua Zhao; Xianpeng Yu; Quan Li; Shuzheng Lv; Fang Chen; Tengyong Jiang
Journal:  Int Heart J       Date:  2017-05-23       Impact factor: 1.862

4.  SYNTAX score II in patients with coronary artery disease undergoing percutaneous mitral repair with the MitraClip.

Authors:  Slayman Obeid; Adrian Attinger-Toller; Maurizio Taramasso; Giovanni Pedrazzini; Gabor Suetsch; Fabienne Landolt; Fatih Karbeyaz; Hector Rodriguez; Daniel Sürder; Tiziano Moccetti; Fabian Nietlispach; Francesco Maisano
Journal:  Int J Cardiol       Date:  2017-02-24       Impact factor: 4.164

5.  Usefulness of SYNTAX score II in complex percutaneous coronary interventions in the setting of acute coronary syndrome.

Authors:  Azzarelli Salvatore; Marouane Boukhris; Simona Giubilato; Salvatore Davide Tomasello; Marine Castaing; Rocco Giunta; Francesco Marzà; Hosam Mohamad Abdelbasset; Hazem Khamis; Alfredo Ruggero Galassi
Journal:  J Saudi Heart Assoc       Date:  2015-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.